BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 29663369)

  • 21. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
    Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1α,25-dihydroxyvitamin D3 acts via transforming growth factor-β to up-regulate expression of immunosuppressive CD73 on human CD4+ Foxp3- T cells.
    Mann EH; Chambers ES; Chen YH; Richards DF; Hawrylowicz CM
    Immunology; 2015 Nov; 146(3):423-31. PubMed ID: 26251265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression.
    Schneider E; Winzer R; Rissiek A; Ricklefs I; Meyer-Schwesinger C; Ricklefs FL; Bauche A; Behrends J; Reimer R; Brenna S; Wasielewski H; Lauten M; Rissiek B; Puig B; Cortesi F; Magnus T; Fliegert R; Müller CE; Gagliani N; Tolosa E
    Nat Commun; 2021 Oct; 12(1):5911. PubMed ID: 34625545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection.
    Mahamed DA; Toussaint LE; Bynoe MS
    Infect Immun; 2015 Feb; 83(2):721-9. PubMed ID: 25452548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
    Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
    Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.
    Gao ZW; Wang HP; Lin F; Wang X; Long M; Zhang HZ; Dong K
    BMC Cancer; 2017 Feb; 17(1):135. PubMed ID: 28202050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
    Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
    IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Shayan G; Kansy BA; Gibson SP; Srivastava RM; Bryan JK; Bauman JE; Ohr J; Kim S; Duvvuri U; Clump DA; Heron DE; Johnson JT; Hershberg RM; Ferris RL
    Clin Cancer Res; 2018 Jan; 24(1):62-72. PubMed ID: 29061643
    [No Abstract]   [Full Text] [Related]  

  • 29. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
    Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
    Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
    Nguyen N; Bellile E; Thomas D; McHugh J; Rozek L; Virani S; Peterson L; Carey TE; Walline H; Moyer J; Spector M; Perim D; Prince M; McLean S; Bradford CR; Taylor JM; Wolf GT;
    Head Neck; 2016 Jul; 38(7):1074-84. PubMed ID: 26879675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.
    Liu JF; Wu L; Yang LL; Deng WW; Mao L; Wu H; Zhang WF; Sun ZJ
    J Exp Clin Cancer Res; 2018 Mar; 37(1):44. PubMed ID: 29506555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
    Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
    Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
    Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
    Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
    Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
    Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
    Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
    Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
    Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.
    Liu JF; Ma SR; Mao L; Bu LL; Yu GT; Li YC; Huang CF; Deng WW; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Oncol; 2017 Feb; 11(2):235-247. PubMed ID: 28102051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.